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Background: MELD-based allocation for liver transplantation follows the “sickest-patient-first” strategy. The latter
patients present with both, decreased immune competence and poor kidney function which is further impaired by
immunosuppressants.
Methods/Design: In this prospective observational study, 50 patients with de novo low-dose standard Advagraf®-based
immunosuppression consisting of Advagraf®, Mycophenolat-mofetil and Corticosteroids after liver transplantation will be
evaluated. Advagraf® trough levels of 7-10 μg/l will be reached at the end of the first postoperative week. Immunostatus,
infectious complications, graft and kidney function are compared between patients with a pretransplant calculated
MELD-score of ≤20 and >20. Each group comprises of 25 consecutive patients. Prior to liver transplantation and on the
postoperative days 1, 3 and 7, the patients’ graft function (LiMAx test) will be evaluated. On the postoperative days 3, 5
and 7 the patients’ immune status will be evaluated by the measurement of their monocytic HLA-DR status.
Infectious complications (CMV-reactivation, wound infection, urinary tract infection, and pneumonia), graft- and kidney
function will be analysed on day 0, within the first week, and 1, 3, 6, 9 and 12 months after liver transplantation.
Discussion: This study was designed to assess the effect of a standard low-dose Calcineurin inhibitor-based
immunosuppression regime with Advagraf® on the rate of infectious complications, graft and renal function after
liver transplantation.
Trial registration: The trial is registered at “Clinical Trials” (www.clinicaltrials.gov), NCT01781195.
Keywords: Advagraf®, Prospective observational study, MELD-score, Liver function, LiMAx test, Infection rate,
HLA-DR status, ImmunostatusBackground
Liver transplantation (LT) is the only curative treatment
for patients with decompensated liver cirrhosis. The
model for end-stage liver disease score (MELD-score) is
used for the prioritization of patients awaiting LT [1].
The MELD-score was initially developed to evaluate the
prognosis after transjugular intrahepatic porto-systemic
shunt (TIPS). The laboratory parameters creatinine, biliru-
bin, and international normalized ratio (INR) are needed
for calculation of this score [1]. Nowadays, the MELD-* Correspondence: Peter.Schemmer@med.uni-heidelberg.de
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unless otherwise stated.score is also used to allocate grafts for LT. The calculated
MELD-scores of patients waiting for LT usually range be-
tween 6 and 40 [2].
Sawitzki et al. described markers that could be used to
determine a patient’s immune status. This would make it
possible to tailor the extent of the individual’s immuno-
suppression therapy after LT. However, the lowest possible
dose of immunosuppressant needs to be determined indi-
vidually in order to minimize side effects of immunosup-
pression while also avoiding an increase in the rejection
rate [3]. The patient’s immune status can be evaluated by
the measurement of B-cell sensitization and soluble bio-
markers like CD30 [4,5]. In addition, the immune status
after LT, sepsis, injuries, and surgery can be evaluated byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Richter et al. BMC Surgery 2014, 14:64 Page 2 of 6
http://www.biomedcentral.com/1471-2482/14/64the monocytic HLA-DR status. A decreased monocytic
HLA-DR status is indicative of an impaired immune com-
petence [6].
In this context, it would be interesting to investigate to
what degree a patient’s HLA-DR status corresponds to the
labMELD-/Na-MELD-score and to measure the liver
function with the LiMAx test. Furthermore, this trial aims
to assess whether or not high-MELD patients (MELD-
score >20) can benefit from a low-dose, prolonged-release
immunosuppression with Advagraf®.
HLA-DR belongs to the major histocompatibility com-
plex (MHC)-II family and is important for antigen pres-
entation to CD4 + -T-cells [6,7]. Monocytes express
HLA-DR on their surface, which can easily be detected by
flow cytometry [6]. As mentioned above, the monocytic
HLA-DR status has been used to evaluate the immune
status after surgery, trauma, or during sepsis [6]. More-
over, the decreased monocytic function found during sep-
sis may be due to a diminished HLA-DR expression [8].
Granulocyte-Macrophage Colony-Stimulating-Factor
(GM-CSF) activates monocytes and prevents apoptosis,
in addition, GM-CSF increases monocytic HLA-DR ex-
pression [8]. Havemann et al. measured the monocytic
HLA-DR status after LT in 20 patients and reported
that a decreased monocytic HLA-DR status was associ-
ated with the risk of sepsis after LT. The risk of sepsis
increases with the administration of an elevated Pred-
nisolone dosage [7,9]. Administering reduced doses of
Prednisolone may prevent patients with decreased
monocytic HLA-DR statuses from becoming septic [7].
In order to allow for multi-center trials on the mono-
cytic HLA-DR status and in an effort to index a patient’s
immune status, a standardized BD Quantibrite™ HLA-
DR/monocyte reagent was developed by Döcke et al. [6].
For consistent results, the blood should be stored on ice
in EDTA tubes and must be analyzed within 4 hours
after extraction [6].
The LiMAx test is useful for pre- and postoperative
examinations of patients undergoing extensive liver re-
sections to determine both, the risk of postoperative
liver failure and liver function. The same applies to pa-
tients after LT [10]. The LiMAx test is usually done at the
patient’s bedside. Patients are required to lay in bed and
avoid eating or smoking within 3 hours prior to being
given 13C-Methacetin infusion. The enzyme CYP1A2 is
exclusive for hepatocytes and metabolizes 13C-Methacetin
to Paracetamol and 13CO2. Thus the
13CO2/
12CO2 ratio in
the exhaled air correlates with liver function [11].
Unlike the LiMAX test, the sole use of laboratory pa-
rameters (e.g. bilirubin, ammonia, INR, and glutamatde-
hydrogenase) is not optimal for analyzing patients’ graft
function, since bilirubin levels are dependent on pre-
operative levels and indicate transplant failure with a
delay of a few days. An increased INR can also be foundas a consequence of bleeding, disseminated intravascular
coagulation (DIC) or as a side effect of several medica-
tions [10]. Early recognition of graft dysfunction is ne-
cessary as hepatic dysfunction affects metabolism and
elimination of Tacrolimus with the need of future dose
adjustments [12].
Since the MELD-score is often used for graft allocation
before LT and the underlying laboratory values are
dependent on the methods used at the time of measure-
ment, it is possible for the MELD-scores to vary signifi-
cantly among the different laboratories [13,14]. It would be
interesting to investigate the correlation between the pre-
operative MELD-score and the LiMAx results, and deter-
mine whether or not this correlation has any influence on
the patient’s preoperative immunostatus (HLA-DR status).
At our institution, a Tacrolimus-based immunosup-
pression (Advagraf®, Prograf®) belongs to the standard
immunosuppression for patients undergoing LT.
Negative side effects of Calcineurin inhibitors (CNI)
are, among others, renal impairment and infectious
complications [15]. High-MELD patients often present
with a limited renal function as creatinine is one compo-
nent of the MELD-score [1]. The combination of CNI
application and higher MELD-scores increases the risk
of renal impairment [15]. Furthermore it has been hy-
pothesized that high-MELD recipients have decreased
immune competence [16] and can therefore benefit from
the lowest possible doses of immunosuppressant drugs
after LT. Low-dose Advagraf® with aimed trough levels
of Tacrolimus at the end of the first week after LT
should protect patients, especially high-MELD patients,
from negative side effects of CNI, especially with regard
to renal function and infection rate, while simultan-
eously promoting no increase in the rate of rejection.
Furthermore, it is assumed that patients with a MELD-
score ≤20 also benefit from this immunosuppressive
regime.
The aim of this study is to evaluate the effectiveness of
a low-dose Calcineurin inhibitor-based immunosuppres-
sive regime with Advagraf® where aimed trough levels of
Tacrolimus are reached at the end of the first week after
liver transplantation, in regard to infectious complica-
tions and both, graft and renal function.
Methods/Design
Study population
The study population consists of patients scheduled for LT
for any indication. Inclusion criteria are age of >18 years
and <65 years, first transplantation, initial immunosuppres-
sion with Advagraf®, Corticosteroids, and Mycophenolat-
mofetil (MMF) with surgery and immediate postoperative
treatment in the Department of General-, Visceral- and
Transplant Surgery at the University Hospital of
Heidelberg.
Table 2 CMV-Prophylaxis
CMV- positive donor Valganciclovir for 3 months:
- 2 × 450 mg/d per os during the
1st and 2nd week after LT
- 1 × 450 mg/d per os thereafter
- Reduced dosages in case
of renal dysfunction creatinine
clearance (ml/min):
- 40-59: 1 × 450 mg/d
- 25-39: 450 mg every 2nd day
- 10-24: 450 mg 2x/week
- Patients under dialysis:
450 mg 2x/week
Ganciclovir i.v.:
- 2x/d 5 mg/kg
- Reduced dosages in case
of renal dysfunction creatinine
clearance (ml/min):
- 49-10: 1x/d 2,5 mg/kg
- <10: 1,25 mg/kg 2x/week
- Patients under dialysis:
1x/d 1,25 mg/kg
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transplantation, and the presence of acute infections
(CMV-reactivation, pneumonia, urinary tract infection,
wound infection, and reactivation of hepatitis B/C). The
individual criterion for discontinuation is the patient’s
withdrawal of written consent.
The study protocol has been approved by the ethics
committee, University of Heidelberg (S-577/2012).
Study objectives
The primary objective is to evaluate the rate of infec-
tious complications in the surrounding of pre-existing
reduced immune competence in patients after LT under
standard CNI-based immunosuppression with Advagraf®,
MMF and Urbason (Table 1).
Patients with grafts from CMV- positive donors re-
ceive standard CMV-prophylaxis (Table 2).
As secondary parameters the correlation between the
patients’ preoperative HLA-DR statuses, MELD-scores
and liver functions measured by the LiMAx-Test and the
correlation between the patients’ postoperative HLA-DR
statuses and liver function measured by the LiMAx-Test
will be assessed. Furthermore infection rate, graft- and
kidney function over time will be analysed and compared
between the two groups.
Clinically relevant measures of liver function (serum
bilirubin, INR, serum transaminase peaks) and kidney
function (creatinine, glomerular filtration rate (GFR)) as
well as episodes of rejection will be documented.
Design and trial flow
For participation in this prospective, mono-centric obser-
vational study, informed written consent is mandatory.
We will evaluate 50 patients, including 25 consecutive pa-
tients with a calculated pretransplant MELD-score of >20
and 25 consecutive patients with a calculated pretransplant
MELD-score of ≤20. Infectious complications (CMV-reacti-
vation, wound infection, urinary tract infection, and pneu-
monia), graft- and kidney function will be analysed on day
0, within the first week after LT, and 1, 3, 6, 9 and
12 months after LT.Table 1 Immunosuppression regime
Urbason Day 0: 2 × 125 mg i.v.
1. POD 2 × 80 mg i.v.
2. POD 2 × 40 mg i.v.
3. POD 2 × 20 mg i.v.
4. POD 1 × 40 mg i.v./p.o.
MMF 2 × 1 g/day Start within 12 h after LT
Advagraf® 1 × 0.1 mg/kg/day Start within 12 h after LT; aimed
trough level at the end of the
1st week 7-10 μg/l
i.v. = intra-venous, MMF =Mycophenolat-mofetil, p.o. = per os,
POD = Postoperative day.Immediately before LT and on postoperative day (POD)
3, 5, and 7, the patients’ immune status will be determined
by the measurement of their HLA-DR status with the BD
Quantibrite™ HLA-DR/monocyte test. The patients’ liver
functions will be evaluated with the LiMAx test prior to
LT and on POD 1, 3, and 7 (Figure 1).
Sample size calculation
This is an observational pilot study. Therefore, no sam-
ple size calculation was performed. The sample size of
50 patients is resulting of the feasibility of patient re-
cruitment within one year.Documentation and data handling
Protocol-required information will be documented in
the case report form and reviewed and signed by the in-
vestigator or by a designated sub-investigator.Statistical methods
This exploratory data analysis will be performed calcu-
lating appropriate summary measures for the empirical
distribution of the parameters. Correlation coefficients,
such as the Spearman Coefficient, will be determined in
connection with the MELD-score and all other correla-
tions will be expressed using the Pearson Correlation
Coefficient. The comparison of infection rates between
the two groups will be analyzed using the chi-squared
test. Continuous parameters will be analyzed using the t-
test. Resulting p-values will be interpreted descriptively.
Figure 1 Flow chart of the IMUTECT study. HLA-DR= Human leukocyte antigen DR, LiMAx= Maximal liver function capacity based
on 13C-Methacetin kinetics, LT= Liver transplantation, MELD= Model for end-stage liver disease, POD= Postoperative day.
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The trial will be performed according to the Declaration
of Helsinki. Before starting the trial, the study protocol
was approved by the ethics committee, University of
Heidelberg. Participation is voluntary and patients can
quit the trial at anytime without fear of subsequently re-
ceiving poor medical care or the need to disclose motives
for withdrawal. In case of a patient’s withdrawal, the rele-
vant data will be deleted or the patient may be asked to
give consent for the analysis of the data. Patient names
and all other confidential information are subject to med-
ical confidentiality at the appointment of the German Data
Protection Act. Transmission of data will be done in an
encrypted format. Third party persons have no access to
original documents.
Informed consent will be obtained and validated using
both the physician’s and the patient’s signature.Discussion
The MELD-score was initially designed to estimate the
prognosis of survival after TIPS [1]. Nowadays, it is one of
the key scores used for assessing patients’suitability for a
liver graft by focusing on the patient’s serum creatinine,
bilirubin, and the INR ratios. The MELD-score values usu-
ally range between 6 and 40. Liver allocation follows the
“sickest-patient-first” strategy, which has significantly de-
creased outcome after LT in Germany [17] and increased
total costs associated with transplantation [18].
Advagraf® is a Tacrolimus derivate that must be taken
once daily (in contrast to Prograf® which has to be admin-
istered twice per day). Blood levels of Advagraf® are usuallyincreasing during the first week until the aimed Tacroli-
mus trough levels are reached.
There is evidence that the immune systems of high-
MELD patients are compromised per se, which in turn,
may lead to an increased risk of early infectious complica-
tions. Almost 85% of patients become afflicted with early
infections, which is the most common cause of death soon
after LT [15].
Additionally, poor renal function often occurs in high-
MELD patients in the surrounding of multi-morbidity
and as creatinine levels became a key parameter in the
allocation of liver grafts. Early renal dysfunction after
transplantation has been reported in up to 50% of patients
[19,20]. CNI are well documented as major risk factors for
early renal impairment and are believed to be responsible
for chronic renal failure after LT [15]. Renal function
seems to play a key role in the long-term survival of pa-
tients with higher MELD-scores, therefore, new immuno-
suppression strategies are necessary in order to avoid
CNI-related impairment of the kidney function after LT.
There are several reported strategies aimed at fore-
stalling renal impairment. One investigated method, the
“Bottom-up” immunosuppression regime as described
by Schnitzbauer et al., documented the use of low dos-
ages of immunosuppressants immediately after LT. The
drug dosages were then increased in case of organ rejec-
tion or when patients were stable beyond day 30 [15].
In the context of the “ReSpECT” study, patients received
standard doses of Tacrolimus (trough levels >10 ng/mL)
and Corticosteroids, or MMF and reduced dosages of
Tacrolimus (trough levels ≤8 ng/mL) and Corticosteroids,
or Daclizumab induction and MMF and reduced dosages
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day post-transplantation along with Corticosteroids. Re-
duced dosages of Tacrolimus have been associated with
less nephrotoxicity and do not increase the risk of rejec-
tion [21]. Thus, a low-dose Advagraf®-based immunosup-
pression regime would decrease both the infection rate
(CMV-reactivation, wound infection, urinary tract infec-
tions, and pneumonia) and associated negative side effects
of a CNI-based immunosuppression strategy, especially in
patients with renal impairment. Moreover, the administra-
tion of a “once-daily” formulation of Advagraf® is more
“patient friendly” [22] and has similar efficacy and safety
results as the “twice-daily” formulation of Tacrolimus [23].
In summary, prolonged-release, low-dose Advagraf® is
predicted to better protect patients from CNI side ef-
fects when compared to standard immunosuppression
regimes, while simultaneously maintaining graft func-
tion and not elevating the rate of organ rejection. It has
been hypothesized that especially high-MELD recipients
(MELD-score >20) who have decreased immune compe-
tence and a reduced renal function benefit from low-dose
Advagraf® regime in regard to infectious complications
and renal function. Furthermore, it can be assumed that
every patient would benefit from the clinical application of
this strategy after LT.
We have chosen a prospective observational study de-
sign with a minor sample size as randomization is not
possible in regard to our study objectives. Depending on
the results of this study, a randomized controlled trial
with adjusted study objectives and a major sample size
might be useful in following study protocols.Trial status
Recruiting
Enrolment of the first patient was performed in June 2013.
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